Google’s venture into using artificial intelligence for drug discovery has led to major breakthroughs in mimicking human biology, earning its scientists the Nobel Prize in Chemistry. Now, Isomorphic Labs, the division responsible for developing and commercializing this technology, has secured a $600 million investment led by Thrive Capital, with contributions from Google’s own venture capital arm, GV, and Alphabet.
Isomorphic, originally spun out of Google’s DeepMind lab, is focused on using A.I. to revolutionize the drug discovery process. With software like AlphaFold, which can predict the structure of proteins and other complex behaviors, the company aims to accelerate the development of new drugs and potentially solve all diseases using A.I.
The recent investment will enable Isomorphic to expand its research capabilities, hire top talent, and further develop A.I. models like AlphaFold. The company is already researching treatments for cancer and immune disorders and has secured partnerships with major drug makers like Eli Lilly and Novartis.
Isomorphic’s founder, Demis Hassabis, emphasized the company’s commitment to partnering with long-term investors focused on life sciences. Thrive Capital’s investment is part of a broader trend of betting on A.I. companies, aiming to revolutionize the drug discovery process and potentially create substantial value in the life sciences industry.
Looking ahead, Isomorphic plans to continue making breakthroughs in computational models and potentially move drug candidates to preclinical trials. The company’s ultimate goal is to become a powerhouse in the industry, supported by strategic investments to drive innovation in drug discovery using artificial intelligence.
Note: The image is for illustrative purposes only and is not the original image of the presented article.
